Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-43395 Plus Letrozole Versus CDK4/6 Inhibitors Plus Letrozole in Advanced HR+/HER2- Breast Cancer
NCT07492641Phase 3Recruiting
- Sponsor
- BeOne Medicines
- Start
- May 2026
- Primary completion
- Apr 2029
- Countries
- 16
01
Overview
A Phase 3 trial of bgb-43395 in breast cancer, sponsored by BeOne Medicines. Started May 2026; status: recruiting.
02
Drugs
bgb-43395
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07492641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07492641.